Loading...
•
Jun 30, 2023
Viking Therapeutics Q2 2023 Earnings Report
Announced financial results for the second quarter and six months ended June 30, 2023, and provided an update on its clinical pipeline and other corporate developments.
Key Takeaways
Viking Therapeutics reported positive top-line results from its Phase 2b VOYAGE study of VK2809 in NASH patients, showing up to 55% median liver fat reduction. A Phase 2 study of VK2735 in obesity is planned for 3Q23, and the company anticipates reporting histology data from VOYAGE in the first half of 2024. The company's cash position at the end of the quarter was $393 million.
Reported Positive Top-Line Results from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed NASH, Showing up to 55% Median Liver Fat Reduction; 52 Week Biopsy Results Expected 1H24
Phase 2 Study of Dual GLP-1/GIP Agonist VK2735 in Obesity Planned for 3Q23
Phase 1 Trial of Oral VK2735 Ongoing; Results Expected 4Q23
Strong Quarter-End Cash Position of $393M
Forward Guidance
Viking expects to report histology data from the VOYAGE study in the first half of 2024. The company plans to initiate a Phase 2 trial of VK2735 in obese patients in 3Q23 and expects to report results in the first half of 2024. Initial results from the Phase 1 trial of the oral formulation of VK2735 are expected in 4Q23. Enrollment in the Phase 1b study of VK0214 in X-ALD is expected to be completed in 2H23.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...